Jieun An

Title: Jieun An: Innovator in Cardiac Safety Evaluation

Introduction

Jieun An is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of drug safety evaluation, particularly in assessing cardiac safety using innovative methods.

Latest Patents

Jieun An holds a patent for "Methods for evaluating cardiac safety of drug using cardiomyocytes derived from human stem cells." This patent outlines a method for assessing drug cardiac safety by utilizing human stem cell-derived cardiomyocytes. The process includes several steps: preparing cardiomyocytes by culturing human stem cells, diluting fibronectin in Dulbecco's phosphate buffered saline (DPBS), adding the fibronectin solution to a microelectrode array (MEA) plate, and measuring changes in beat rate, spike amplitude, and field potential duration based on drug addition.

Career Highlights

Jieun An is currently employed at Nexel Co., Ltd., where he continues to advance research in cardiac safety evaluation. His work is pivotal in developing safer pharmaceuticals through innovative methodologies.

Collaborations

Some of his notable coworkers include Donghun Woo and Subin Kim, who contribute to the collaborative efforts in their research projects.

Conclusion

Jieun An's innovative approach to evaluating cardiac safety represents a significant advancement in the pharmaceutical industry. His contributions are essential for ensuring drug safety and efficacy.